Back to results
US 2018/0021376 A1Published application
Naming of KH1 through KH55 good healthy cells synthesizes the KH1 through KH55 proteins
AssigneeRare Antibody Antigen Supply, Inc.
InventorKieu Hoang
Life of this patent
Estimating the term…
Abstract
The present invention provides purified blood plasma products from fraction II+III containing proteins at concentrations useful for the treatment of various diseases and infections including hepatitis B virus. Methods of manufacture and treatment are also provided. The purified blood plasma products regulate levels of immune cells and their proteins in the organs and peripheral blood of treated subjects. Examples of immune cells and associated proteins regulated by the purified blood plasma products include CD62L levels on T cells, CD4+, CD8+, CD28+, and Foxp3+ T cells, B cells, as well as granulocytes and macrophages.
Claims33
An isolated purified IVIG plasma product comprising an isolated purified protein complex containing proteins defined by amino acid sequences SEQ ID NOs 33-37.
An isolated purified IVIG plasma product comprising an isolated purified protein complex containing:
- a first substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 22;
- a second substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 23;
- a third substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 24;
- a fourth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 25;
- a fifth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 26;
- a sixth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 27;
- a seventh substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 28;
- an eighth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 29;
- a ninth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 30;
- a tenth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 31;
- an eleventh substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 32;
- a twelfth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 33;
- a thirteenth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 34;
- a fourteenth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 35;
- a fifteenth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 36;
- and
- a sixteenth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 37.
30 more elements
An isolated purified IVIG plasma product comprising an isolated purified protein complex containing:
- a first substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 33;
- a second substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 34;
- a third substantially pure protein having at least 90% homology to amino acid SEQ ID NO:
- 35;
- a fourth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 36;
- and
- a fifth substantially pure protein having at least 90% homology to amino acid sequence SEQ ID NO:
- 37.
8 more elements
An isolated purified IVIG plasma product comprising an isolated purified protein complex containing:
- a first substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 22, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 22;
- a second substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 23, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 23;
- a third substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 24, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 24;
- a fourth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 25, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 25;
- a fifth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 26, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 26;
- a sixth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 27, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 27;
- a seventh substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 28, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 28;
- an eighth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 29, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 29;
- a ninth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 30, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 30;
- a tenth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 31, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 31;
- an eleventh substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 32, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 32;
- a twelfth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 33, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 33;
- a thirteenth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 34, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 34;
- a fourteenth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 35, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 35;
- a fifteenth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 36, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 36;
- and
- a sixteenth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 37, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 37.
46 more elements
An isolated purified IVIG plasma product comprising an isolated purified protein complex containing:
- a first substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 33, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 33;
- a second substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 34, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 34;
- a third substantially pure protein having at least 80% homology to amino acid SEQ ID NO:
- 35, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 35;
- a fourth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 36, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 36;
- and
- a fifth substantially pure protein having at least 80% homology to amino acid sequence SEQ ID NO:
- 37, wherein said substantially pure protein has the same activity as the protein defined by amino acid sequence SEQ ID NO:
- 37.
13 more elements
A method of treating hepatitis B in a patient comprising:
- administering to said patient an effective dose of an isolated purified IVIG plasma product, wherein the isolated purified IVIG plasma product comprises:
- a first protein defined by amino acid sequence SEQ ID NO:
- 33;
- a second protein defined by amino acid sequence SEQ ID NO:
- 34;
- a third protein defined by amino acid sequence SEQ ID NO 35;
- a fourth protein defined by amino acid sequence SEQ ID NO 36;
- and
- a fifth protein defined by amino acid sequence SEQ ID NO 37.
6 more elements
A method of manufacturing an isolated purified IVIG plasma product containing proteins defined by amino acid sequences SEQ ID NOs 33-37 comprising:
- a) obtaining a fraction II+III paste from human blood plasma;
- b) suspending and diluting the fraction II+III paste at a ratio of 1:17;
- c) adjusting the pH of the diluted fraction II+III paste to a pH of 5.2 to produce an adjusted fraction II+III paste;
- d) adding ethanol to the adjusted fraction II+III paste to produce a 17% ethanol fraction II+III product;
- e) press filtering the 17% ethanol fraction II+III product and collecting a filtrate comprising fraction III;
- f) concentrating the filtrate by ultrafiltration to form a 100 k ultrafiltrate;
- g) adjusting the pH of the 100 k ultrafiltrate to a pH of 4.0;
- h) filtering the pH adjusted ultrafiltrate using a 0.45 um filter and collecting a filtered product;
- and
- i) nanofiltrating the filtered product with a 50 nm filter to obtain a final product.
7 more elements
A method of manufacturing an isolated purified IVIG plasma product containing proteins defined by amino acid sequences SEQ ID NOs 22-37 comprising:
- a) obtaining a fraction II+III paste from human hepatitis B immune globulin having high levels of hepatitis B surface antigen;
- b) suspending and diluting the fraction II+III paste at a ratio of 1:17;
- c) adjusting the pH of the diluted fraction II+III paste to a pH of 5.2 to produce an adjusted fraction II+III paste;
- d) adding ethanol to the adjusted fraction II+III paste to produce a 17% ethanol fraction II+III product;
- e) press filtering the 17% ethanol fraction II+III product and collecting a filtrate comprising fraction III;
- f) concentrating the filtrate by ultrafiltration to form a 100 k ultrafiltrate;
- g) adjusting the pH of the 100 k ultrafiltrate to a pH of 4.0;
- h) filtering the pH adjusted ultrafiltrate using a 0.45 um filter and collecting a filtered product;
- and
- i) nanofiltrating the filtered product with a 50 nm filter to obtain a final product.
7 more elements
A method of producing an isolated purified IVIG plasma product containing proteins defined by amino acid sequences SEQ ID NOs 22-37, and 51 comprising:
- a) manufacturing a non-sterile final bulk of normal immunoglobulin;
- b) manufacturing a non-sterile final bulk of hepatitis B immune globulin;
- c) creating a immunoglobulin mixture comprising 80% of the non-sterile final bulk of normal immunoglobulin and 20% of the non-sterile final bulk of hepatitis B immune globulin;
- d) performing sterile filtration on the immunoglobulin mixture and collecting a final product.
1 more element
Dependencies are inferred from the claim text.